Comparison of the efficacy and safety of rivaroxaban and low-molecular-weight heparin in Chinese lung cancer patients with nonhigh-risk pulmonary embolism

Gervaso L, Dave H, Khorana AA. Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2021;3(2):173–90. https://doi.org/10.1016/j.jaccao.2021.03.001.

Article  Google Scholar 

Li Y, Shang Y, Wang W, Ning S, Chen H. Lung cancer and pulmonary embolism: what is the relationship? A review. J Cancer. 2018;9(17):3046. https://doi.org/10.7150/jca.26008.

Article  CAS  Google Scholar 

Lee A, Parpia S, Julian J, Rickles F, Prins M, Levine M. Predictors of recurrent thrombosis and anticoagulant-related bleeding in patients with cancer. J Clin Oncol. 2009;27(15_suppl):9565. https://doi.org/10.1200/jco.2009.27.15_suppl.9565.

Article  Google Scholar 

Qian X, Fu M, Zheng J, Zhou J, Zhou J. Driver Genes Associated With the Incidence of Venous Thromboembolism in Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Front Oncol. 2021;11:680191-. https://doi.org/10.3389/fonc.2021.680191.

Article  Google Scholar 

Steuer CE, Behera M, Kim S, Patel N, Chen Z, Pillai R, et al. Predictors and outcomes of venous thromboembolism in hospitalized lung cancer patients: A Nationwide Inpatient Sample database analysis. Lung Cancer. 2015;88(1):80–4. https://doi.org/10.1016/j.lungcan.2015.01.022.

Article  Google Scholar 

Chiari R, Ricciuti B, Landi L, Morelli AM, Delmonte A, Spitaleri G, et al. ROS1-rearranged Non-small-cell Lung Cancer is Associated With a High Rate of Venous Thromboembolism: Analysis From a Phase II, Prospective, Multicenter, Two-arms Trial (METROS). Clin Lung Cancer. 2020;21(1):15–20. https://doi.org/10.1016/j.cllc.2019.06.012.

Article  Google Scholar 

Moik F, Chan WE, Wiedemann S, Hoeller C, Tuchmann F, Aretin MB, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood. 2021;137(12):1669–78. https://doi.org/10.1182/blood.2020007878.

Article  CAS  Google Scholar 

Roopkumar J, Poudel SK, Gervaso L, Reddy CA, Velcheti V, Pennell NA, et al. Risk of thromboembolism in patients with ALK-and EGFR-mutant lung cancer: a cohort study. J Thromb Haemost. 2021;19(3):822–9. https://doi.org/10.1111/jth.15215.

Article  CAS  Google Scholar 

Konstantinides SV, Meyer G, Becattini C, Bueno H, Geersing GJ, Harjola VP, et al. 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2020;41(4):543–603. https://doi.org/10.1093/eurheartj/ehz405.

Article  Google Scholar 

Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021;5(4):927–74. https://doi.org/10.1182/bloodadvances.2020003442.

Article  CAS  Google Scholar 

Streiff MB, Holmstrom B, Angelini D, Ashrani A, Elshoury A, Fanikos J, et al. Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19(10):1181–201. https://doi.org/10.6004/jnccn.2021.0047.

Article  Google Scholar 

Streiff MB, Holmstrom B, Angelini D, Ashrani A, Bockenstedt PL, Chesney C, et al. NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. J Natl Compr Canc Netw. 2018;16(11):1289–303. https://doi.org/10.6004/jnccn.2018.0084.

Article  Google Scholar 

Lee AYY, Kamphuisen PW, Meyer G, Bauersachs R, Janas MS, Jarner MF, et al. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. JAMA. 2015;314(7):677–86. https://doi.org/10.1001/jama.2015.9243.

Article  CAS  Google Scholar 

Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018;36(20):2017–23. https://doi.org/10.1200/jco.2018.78.8034.

Article  CAS  Google Scholar 

Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, et al. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials. Lancet Haematol. 2014;1(1):e37-46. https://doi.org/10.1016/s2352-3026(14)70018-3.

Article  Google Scholar 

McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020;18(2):411–21. https://doi.org/10.1111/jth.14662.

Article  CAS  Google Scholar 

Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. N Engl J Med. 2020;382(17):1599–607. https://doi.org/10.1056/NEJMoa1915103.

Article  CAS  Google Scholar 

Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018;378(7):615–24. https://doi.org/10.1056/NEJMoa1711948.

Article  CAS  Google Scholar 

Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2020;38(5):496–520. https://doi.org/10.1200/jco.19.01461.

Article  Google Scholar 

Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566–81. https://doi.org/10.1016/s1470-2045(19)30336-5.

Article  Google Scholar 

Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287–97. https://doi.org/10.1056/NEJMoa1113572.

Article  Google Scholar 

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808. https://doi.org/10.1056/NEJMoa1302507.

Article  CAS  Google Scholar 

Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499–510. https://doi.org/10.1056/NEJMoa1007903.

Article  CAS  Google Scholar 

Centers for Disease Control and Prevention International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Accessed 22 Dec 2020.

Centers for Disease Control and Prevention International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM). Accessed 22 Dec 2020.

Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692–4. https://doi.org/10.1111/j.1538-7836.2005.01204.x.

Article  CAS  Google Scholar 

Yang D, Dalton JE, editors. A unified approach to measuring the effect size between two groups using SAS2012.

Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med. 2015;34(28):3661–79. https://doi.org/10.1002/sim.6607.

Article  Google Scholar 

Hill H, Robinson M, Lu L, Slaughter D, Amin A, Mileham K, et al. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy. Thromb Res. 2021;208:71–8. https://doi.org/10.1016/j.thromres.2021.10.014.

Article  CAS  Google Scholar 

Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to Prevent Venous Thromboembolism in Patients with Cancer. N Engl J Med. 2019;380(8):711–9. https://doi.org/10.1056/NEJMoa1814468.

Article  CAS  Google Scholar 

Chen D-Y, Tseng C-N, Hsieh M-J, Lan W-C, Chuang C-K, Pang S-T, et al. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism. JAMA Netw Open. 2021;4(2):e2036304-e. https://doi.org/10.1001/jamanetworkopen.2020.36304.

Article  Google Scholar 

Wysokinski WE, Houghton DE, Casanegra AI, Vlazny DT, Bott-Kitslaar DM, Froehling DA, et al. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Am J Hematol. 2019;94(11):1185–92. https://doi.org/10.1002/ajh.25604.

Article  CAS  Google Scholar 

Costa OS, Kohn CG, Kuderer NM, Lyman GH, Bunz TJ, Coleman CI. Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism. Blood Adv. 2020;4(17):4045–51. https://doi.org/10.1182/bloodadvances.2020002242.

Article  CAS  Google Scholar 

Riaz IB, Fuentes HE, Naqvi SAA, He H, Sipra QR, Tafur AJ, et al. Direct Oral Anticoagulants Compared With Dalteparin for Treatment of Cancer-Associated Thrombosis: A Living, Interactive Systematic Review and Network Meta-analysis. Mayo Clin Proc. 2022;97(2):308–24. https://doi.org/10.1016/j.mayocp.2020.10.041.

Article  CAS  Google Scholar 

Overvad TF, Larsen TB, Søgaard M, Albertsen IE, Ording AG, Noble S, et al. Cancer-associated venous thromboembolism and the non-vitamin K antagonist oral anticoagulants: a review of clinical outcomes and patient perspectives. Expert Rev Cardiovasc Ther. 2020;18(11):791–800. https://doi.org/10.1080/14779072.2020.1822167.

Article  CAS  Google Scholar 

Gu ZC, Yan YD, Yang SY, Shen L, Kong LC, Zhang C, et al. Direct versus conventional anticoagulants for treatment of cancer associated thrombosis: a pooled and interaction analysis between observational studies and randomized clinical trials. Ann Transl Med. 2020;8(4):95. https://doi.org/10.21037/atm.2019.12.152.

Article  CAS  Google Scholar 

Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C, et al. Laboratory assessment of rivaroxaban: a review. Thromb J. 2013;11(1):11. https://doi.org/10.1186/1477-9560-11-11.

Article  CAS  Google Scholar 

Jakowenko N, Nguyen S, Ruegger M, Dinh A, Salazar E, Donahue KR. Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system. Thromb Res. 2020;196:276–82. https://doi.org/10.1016/j.thromres.2020.09.002.

Article  CAS  Google Scholar 

Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer. N Engl J Med. 2019;380(8):720–8. https://doi.org/10.1056/NEJMoa1814630.

Article  CAS  Google Scholar 

Lee JH, Hyun DG, Choi CM, Lee JC, Kim WS, Oh YM, et al. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer. Respiration. 2019;98(3):203–11. https://doi.org/10.1159/000499895.

Article  CAS  Google Scholar 

Cha SI, Shin KM, Lim JK, Yoo SS, Lee SY, Lee J, et al. Pulmonary embolism concurrent with lung cancer and central emboli predict mortality in patients with lung cancer and pulmonary embolism. J Thorac Dis. 2018;10(1):262–72. https://doi.org/10.21037/jtd.2017.12.32.

Article  Google Scholar 

Berghaus TM, Haeckel T, Behr W, Wehler M, von Scheidt W, Schwaiblmair M. Central thromboembolism is a possible predictor of right heart dysfunction in normotensive patients with acute pulmonary embolism. Thromb Res. 2010;126(3):e201–5. https://doi.org/10.1016/j.thromres.2010.06.009.

Article  CAS 

留言 (0)

沒有登入
gif